- Varian is a global leader in the field of radiation therapy with around 50% market share.
- The radiation therapy market is a growing market, driven by an increasing cancer rate globally and increasing adoption of radiation therapy in emerging markets.
- Varian is a very innovative company, driving business growth through successful product launches and gaining market share.
- It is well positioned to expand into adjacent fast-growing markets to sustain its future growth through its R&D effort and acquisitions.
1 in 2 people will be diagnosed with cancer in their lifetime and nearly half of cancer patients have radiation therapy at some point during their cancer treatment. Varian is a global market leader in the field of radiation therapy, developing devices including linear accelerators and software for treating cancer. Its vision is a world without fear of cancer. Varian aims to increase the number of patients worldwide cared for with its technology from 3 million today to 6 million by 2022.
With the advance of medical technologies and improving diets, global average life expectancy has increased. Sadly, as we live longer, cancer risk also increases. This backdrop creates a growing demand for radiation therapy as it is an effective and relatively affordable treatment option for cancer patients. This market is estimated to grow at 4% annually to $6.3 billion in 2022. The market for radiation therapy equipment is consolidated, dominated by two major players Varian and Elekta. They compete on innovation and technology, which results in better clinical outcomes and lower side-effects for patients.
Varian’s strategy is to transform itself from a global leader in radiation therapy to be a front-runner in multi-disciplinary integrated cancer care solutions. This approach helps it strengthen its leadership in radiation therapy, expand its addressable market and extend its global footprint. One of its plans is to expand into the adjacent markets of Care Coordination and Interventional Oncology. Care Coordination is a fast growing market due to the increasing complexity of cancer care. The market is expected to grow 20% annually to $6 billion in 2022. Varian introduced its 360 Oncology care management platform in 2016, bringing together radiation, medical and surgical oncology, social services and primary care physicians to facilitate true coordinated care. This platform enables doctors to provide the highest quality, evidence-based care plan and best clinical outcome possible. Interventional Oncology is another fast growing adjacent market, estimated to grow at 8% annually to 2022. Varian launched Rapidsphere in 2018, a cancer imaging software for the interventional oncology market. The software can aggregate unstructured treatment and imaging data from diverse systems to show a comprehensive view of a patient’s diagnostic imaging and treatment history.
To maintain its competitiveness, Varian is committed to innovation and generally spends 8% of its sales on research and development. There are numerous examples which demonstrate its leadership in innovation. Varian introduced a new cancer treatment device Halycon in 2017 to target emerging markets. Halycon aims to reduce the total cost of ownership and provide faster treatment times to meet the high demand for high-throughput cancer centres in the emerging markets. It also launched a new proton therapy system ProBeam 360 in 2018 with 30% smaller footprint and faster treatment times.
Varian is a pioneer in radiation therapy and we believe it will play an even bigger role in cancer care solutions in the future.
We invest in this stock for the following reasons:
- Secular market growth: Radiation therapy is a growing market driven by the growing prevalence of cancer and the increasing adoption of radiation therapy in emerging markets.
- Dominant market leader: Varian has around 50% market share in radiation therapy and is increasing its share.
- Innovative excellence: Varian is fully committed to innovation. Its technological leadership is evidenced by the successful launch of Halycon, which was selected as one of 2018’s most exceptional innovations in science and technology.
- Expanding addressable market: Varian has successfully expanded into faster growing adjacent markets through internal development and acquisition.
Risks include: the price of shares (“Shares”) in FP WHEB Sustainability Fund (“Fund”) may increase or decrease and you may not get back the amount originally invested, for reasons including adverse market and foreign exchange rate movements. Past performance is not a guide to future returns. The Fund invests in equities and is exposed to price fluctuations in the equity markets, and focuses on investments in mid-sized companies in certain sectors so its performance may not correlate closely with the MSCI World Index (the Fund’s benchmark). For full risks, please see fund prospectus on www.whebgroup.com.
General: This blog, its contents and any related communication (altogether, the “Blog”) is issued by WHEB Asset Management LLP (“WHEB Asset Management”). It is intended for information purposes only and does not constitute or form part of any offer or invitation to buy or sell any security including any shares in the FP WHEB Sustainability Fund, including in the United States. It should not be relied upon to make an investment decision in relation to Shares in the FP WHEB Sustainability Fund or otherwise; any such investment decision should be made only on the basis of the Fund scheme documents and appropriate professional advice. This Blog does not constitute advice of any kind, investment research or a research recommendation, is in summary form and is subject to change without notice. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. WHEB Asset Management has exercised reasonable care in preparing this Blog including using reliable sources, however, makes no representation or warranty relating to its accuracy, reliability or completeness or whether any future event may or may not occur. This Blog is only made available to recipients who may lawfully receive it in accordance with applicable laws, regulations and rules and binding guidance of regulators. WHEB Asset Management LLP is registered in England and Wales with number OC 341489 and has its registered office at 7 Cavendish Square, London, W1G 0PE. WHEB Asset Management LLP is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 496413. FundRock Partners Limited (formerly Fund Partners Limited) is the Authorised Corporate Director of the Fund and is authorised and regulated by the Financial Conduct Authority with Firm Reference Number 469278 and has its registered office at 8-9 Lovat Lane, London EC3R 8DW. The state of the origin of the Fund is England and Wales. The Representative in Switzerland is ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zurich, whilst the Paying Agent is Bank Vontobel Ltd, Gotthardstrasse 43, CH-8022 Zurich. The relevant documents such as the prospectus, the key investor information document (KIIDs), the Articles of Association as well as the annual and semi-annual reports may be obtained free of charge from the representative in Switzerland.
The MSCI information may only be used for your internal use, may not be reproduced or re-dissseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com